{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:21:36Z","timestamp":1791206496124,"version":"4.1.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sichuan Medical Association and Specialized scientific research fund projects of HENG RUI","award":["2019HR17"],"award-info":[{"award-number":["2019HR17"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Hypertension and hyperhomocysteinemia (HHcy) have long been associated with adverse cardiovascular and cerebrovascular health outcomes. This study evaluated the effect of individualized administration of folic acid (FA) on homocysteine (Hcy) levels, prothrombotic state, and blood pressure (BP) in patients with H-type hypertension (combination of HHcy and hypertension).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this double-blinded, randomized clinical cohort study, 126 patients with H-type hypertension who were treated at our hospital were randomly divided into treatment and control groups (n\u200a=\u200a55 each). The control group was treated with oral levamlodipine besylate tablets 2.5\u200amg and placebo, once a day (in the morning). The treatment group was first treated with oral levamlodipine besylate 2.5\u200amg and FA tablets 0.8\u200amg, once a day (in the morning), for 12\u200aweeks. Then, in a second 12-week phase, the FA dose was adjusted using the methylene tetrahydrofolate reductase C677 polymorphism genotype. The levels of Hcy and coagulation factors, prothrombotic state parameters, BP, and adverse drug reactions were compared between the 2 groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Pretreatment general patient characteristics, including Hcy levels, were similar between the 2 groups (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&gt;\u200a.05). BP and prothrombotic status did not differ before and after the first phase of treatment (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&gt;\u200a.05). However, Hcy and endothelin-1 (ET-1) levels decreased, while nitric oxide levels increased significantly in the intervention group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&lt;\u200a.05). In the second phase, after 3 months\u2019 treatment with an FA dose adjusted according to methylene tetrahydrofolate reductase C677T genotype, the Hcy and ET-1\/NO levels were significantly decreased in the intervention group and were lower than those after the first treatment phase and lower than in the control group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&lt;\u200a.01). BP, D-dimer levels, and fibrinogen scores were significantly lower after the second treatment phase (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&lt;\u200a.01). There was no significant difference in the incidence of adverse drug reactions between the 2 groups (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&gt;\u200a.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Individualized administration of FA tablets can effectively reduce BP, and Hcy and coagulation factor levels, and significantly improve prothrombotic status in patients with H-type hypertension.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000028628","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T08:05:13Z","timestamp":1642752313000},"page":"e28628","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":25,"title":["Effects of individualized administration of folic acid on prothrombotic state and vascular endothelial function with H-type hypertension"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4465-0059","authenticated-orcid":false,"given":"Song","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaiqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baozhong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangming","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruohan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4465-0059","authenticated-orcid":false,"given":"Hanjun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"R1-20240803","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1186\/s12889-020-8377-6","article-title":"Death burden of high systolic blood pressure in Sichuan Southwest China 1990-2030","volume":"20","author":"Wang","year":"2020","journal-title":"BMC Public Health"},{"key":"R2-20240803","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1080\/10641963.2017.1306540","article-title":"Epidemiological characteristics of hyperhomocysteinemia and H-type hypertension in the elderly in Beijing, China","volume":"39","author":"Ma","year":"2017","journal-title":"Clin Exp Hypertens"},{"key":"R3-20240803","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3109\/10641963.2015.1116547","article-title":"H-type hypertension is an important risk factor of carotid atherosclerotic plaques","volume":"38","author":"Chen","year":"2016","journal-title":"Clin Exp Hypertens"},{"key":"R4-20240803","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1177\/1076029613519849","article-title":"Predicting hyperhomocysteinemia by methylenetetrahydrofolate reductase C677T polymorphism in chinese patients with hypertension","volume":"21","author":"Wang","year":"2015","journal-title":"Clin Appl Thromb Hemost"},{"key":"R5-20240803","doi-asserted-by":"crossref","first-page":"e9068","DOI":"10.1097\/MD.0000000000009068","article-title":"Early neurological deterioration during the acute phase as a predictor of long-term outcome after first-ever ischemic stroke","volume":"96","author":"Geng","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"R6-20240803","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/1573403X16666200511085701","article-title":"What could be the most advantageous therapeutic approach to avoid both arterial and venous thrombosis in hyperhomocysteinemia?","volume":"17","author":"Cacciapuoti","year":"2021","journal-title":"Curr Cardiol Rev"},{"key":"R7-20240803","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/1076029612466285","article-title":"Hyperhomocysteinemia and methylenetetrahydrofolate reductase C677T polymorphism in cerebral veno-sinus thrombosis","volume":"20","author":"Bharatkumar","year":"2014","journal-title":"Clin Appl Thromb Hemost"},{"key":"R8-20240803","doi-asserted-by":"crossref","first-page":"1422788424","DOI":"10.1177\/1076029618780344","article-title":"Polymorphisms C677T and A1298C of MTHFR gene: homocysteine levels and prothrombotic biomarkers in coronary and pulmonary thromboembolic disease","volume":"25","author":"Lupi-Herrera","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"key":"R9-20240803","doi-asserted-by":"crossref","first-page":"103","DOI":"10.23736\/S0026-4806.16.04951-X","article-title":"Analysis of metabolism-related indicators and MTHFR gene polymorphism in patients with H-type hypertension","volume":"108","author":"Tang","year":"2017","journal-title":"Minerva Med"},{"key":"R10-20240803","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/10641963.2017.1281937","article-title":"Associations of methylenetetrahydrofolate reductase C677T genotype with blood pressure levels in Chinese population with essential hypertension","volume":"40","author":"Cheng","year":"2018","journal-title":"Clin Exp Hypertens"},{"key":"R11-20240803","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10067-016-3348-0","article-title":"Associations of methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms with genetic susceptibility to rheumatoid arthritis: a meta-analysis","volume":"36","author":"Cen","year":"2017","journal-title":"Clin Rheumatol"},{"key":"R12-20240803","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3109\/00207454.2014.984295","article-title":"Association between the methylenetetrahydrofolate reductase (MTHFR) gene C677T polymorphism and ischemic stroke in the Chinese population: a meta-analysis","volume":"125","author":"Zhu","year":"2015","journal-title":"Int J Neurosci"},{"key":"R13-20240803","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/ajh\/hpt138","article-title":"The effects of amlodipine and S(\u2212)-amlodipine on vascular endothelial function in patients with hypertension","volume":"27","author":"He","year":"2014","journal-title":"Am J Hypertens"},{"key":"R14-20240803","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3390\/nu8100665","article-title":"Association of MTHFR, SLC19A1 genetic polymorphism, serum folate, vitamin b12 and Hcy status with cognitive functions in Chinese adults","volume":"8","author":"Cai","year":"2016","journal-title":"Nutrients"},{"key":"R15-20240803","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/35025203","article-title":"Atherosclerosis","volume":"407","author":"Lusis","year":"2000","journal-title":"Nature"},{"key":"R16-20240803","doi-asserted-by":"crossref","first-page":"e14910","DOI":"10.1097\/MD.0000000000014910","article-title":"Associations of plasma LP(a), Hcy and D-D levels with the subtype of ischemic cerebrovascular disease","volume":"98","author":"Tang","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"R17-20240803","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s12032-014-0403-z","article-title":"Apoptosis and calcification of vascular endothelial cell under hyperhomocysteinemia","volume":"32","author":"Fang","year":"2015","journal-title":"Med Oncol"},{"key":"R18-20240803","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/cbin.10077","article-title":"Inhibition of ATP-induced calcium influx by homocysteine in human umbilical vein endothelial cells","volume":"37","author":"Cortes","year":"2013","journal-title":"Cell Biol Int"},{"key":"R19-20240803","first-page":"3279","article-title":"The changes of serum of Hcy, CYSC, HS-CRP, ET-1 and FIB in patients with primary cerebral infarction","volume":"35","author":"Ma","year":"2019","journal-title":"Acta Med Mediterr"},{"key":"R20-20240803","doi-asserted-by":"crossref","first-page":"579","DOI":"10.5604\/17322693.1102340","article-title":"Hyperhomocysteinemia in patients with cardiovascular disease","volume":"68","author":"Baszczuk","year":"2014","journal-title":"Postepy Hig Med Dosw (Online)"},{"key":"R21-20240803","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.2147\/DMSO.S267122","article-title":"Joint effects of plasma homocysteine concentration and traditional cardiovascular risk factors on the risk of new-onset peripheral arterial disease","volume":"13","author":"Liu","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"key":"R22-20240803","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/sj.ejhg.5201024","article-title":"Genetic polymorphisms in folate and homocysteine metabolism as risk factors for DNA damage","volume":"11","author":"Botto","year":"2003","journal-title":"Eur J Hum Genet"},{"key":"R23-20240803","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.thromres.2007.05.026","article-title":"MTHFR C677T mutation in central retinal vein occlusion: a case-control study in Chinese population","volume":"121","author":"Gao","year":"2008","journal-title":"Thromb Res"},{"key":"R24-20240803","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s11906-005-0005-4","article-title":"Is hypertension a prothrombotic state?","volume":"7","author":"Varughese","year":"2005","journal-title":"Curr Hypertens Rep"},{"key":"R25-20240803","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/sj.jhh.1001051","article-title":"Hypertension and the prothrombotic state","volume":"14","author":"Lip","year":"2000","journal-title":"J Hum Hypertens"},{"key":"R26-20240803","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3177\/jnsv.63.96","article-title":"The impact of supplementation with folic acid on homocysteine concentration and selected lipoprotein parameters in patients with primary hypertension","volume":"63","author":"Baszczuk","year":"2017","journal-title":"J Nutr Sci Vitaminol (Tokyo)"},{"key":"R27-20240803","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.arcmed.2007.07.009","article-title":"The 677\u200aC\/T MTHFR polymorphism is associated with essential hypertension, coronary artery disease, and higher homocysteine levels","volume":"39","author":"Ilhan","year":"2008","journal-title":"Arch Med Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028628","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T03:59:55Z","timestamp":1722743995000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028628"}},"subtitle":["A double-blinded, randomized clinical cohort study"],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000028628","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,21]]},"assertion":[{"value":"2021-04-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}